BMS Opdivo designation a boost for UK early access scheme
This article was originally published in Scrip
Executive Summary
The award of the UK's third "Promising Innovative Medicine" (PIM) designation, to Bristol-Myers Squibb's drug for advanced melanoma Opdivo (nivolumab), is clearly good news for the company and for patients. But it is also something of a vote of confidence in the UK's Early Access to Medicines Scheme (EAMS), amid concerns that the costs of the scheme could deter some companies from using it.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.